This is a type of cancer that starts in the cells that line the surface of the ovary. It's the most common kind of ovarian cancer. There are different subtypes, but they all originate from these surface cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Carboplatin for Epithelial Ovarian Cancer?
Epithelial ovarian cancer is cancer that starts in the epithelium, the thin layer of cells that covers the ovary or lines the nearby fallopian tube. It is by far the most common kind of ovarian cancer. Many cases of its most common form, high-grade serous carcinoma, are now thought to begin at the far end of a fallopian tube before reaching the ovary. Fallopian tube cancer and primary peritoneal cancer (cancer of the lining of the abdomen) arise from the same kind of tissue and are treated the same way, so doctors usually group the three together. The cancer tends to spread across the surfaces inside the abdomen before it causes clear symptoms. When symptoms do appear, they are easy to mistake for digestive or bladder problems: bloating, pain or pressure in the belly or pelvis, feeling full quickly or having trouble eating, and a sudden or frequent need to urinate. As a result, most people are diagnosed after the cancer has already spread beyond the ovaries, which is the main reason it is harder to treat than many other cancers. The term covers several subtypes, mainly serous (high-grade or low-grade), endometrioid, clear cell and mucinous. They grow differently and can call for different treatments, so the subtype named in the pathology report matters.
Like other cancers, epithelial ovarian cancer begins with changes in a cell's DNA that let it grow out of control. Most of those changes build up during a person's lifetime for reasons that usually cannot be pinned down. About one in five cases is linked to an inherited gene change, most often in BRCA1 or BRCA2, the same genes tied to hereditary breast cancer. Lynch syndrome, an inherited condition best known for raising colon cancer risk, also increases ovarian cancer risk. Age is the strongest general risk factor, and about half of cases occur after age 65. A mother, sister or daughter with ovarian cancer, endometriosis, hormone therapy after menopause, obesity, being tall and never having been pregnant are also linked to higher risk. These are associations, not causes: most people with a risk factor never develop the disease, and many who do had no obvious risk factor. Some things are linked to lower risk, including having taken birth control pills (the effect can last for decades after stopping), having given birth, breastfeeding, and having the fallopian tubes tied or removed. People with a BRCA variant or a similar inherited risk may choose, after genetic counseling, to have the ovaries and fallopian tubes removed, which greatly lowers their risk. That surgery ends fertility and brings on menopause if it has not already happened.
There is no reliable screening test for people without symptoms. Large trials found that routine transvaginal ultrasound and CA-125 blood tests did not reduce deaths from ovarian cancer, and false alarms led some people without cancer to have surgery. For that reason the US Preventive Services Task Force recommends against screening people who have no symptoms and are not known to have a high inherited risk. When symptoms raise concern, assessment usually includes a pelvic exam, a transvaginal ultrasound (a small probe placed in the vagina gives a close view of the ovaries) and a CA-125 blood test. CA-125 is a protein that is often high in epithelial ovarian cancer, but endometriosis, other noncancerous conditions and other cancers can also raise it, and it may not be clearly raised in some low-grade cancers. A high result raises suspicion rather than proving cancer. CT (computed tomography) scans of the chest, abdomen and pelvis show whether disease has spread. The diagnosis is confirmed only when a pathologist examines tissue, usually removed during surgery. Surgery and imaging also set the stage, from stage I (cancer limited to one or both ovaries or fallopian tubes) to stage IV (spread beyond the abdomen, such as to fluid around the lungs or to the liver). Stage, subtype and grade together guide treatment. Everyone diagnosed with epithelial ovarian cancer should be offered genetic testing for BRCA1, BRCA2 and other inherited risk genes, ideally at diagnosis. If no inherited change is found, the tumor itself can be tested for BRCA changes. The results help choose treatment and tell blood relatives whether they should consider testing too.
Treatment usually combines surgery and chemotherapy. Surgery aims to remove as much visible cancer as possible: typically the uterus, both ovaries and fallopian tubes, and the omentum (a fatty apron of tissue in the abdomen where this cancer often spreads), along with lymph nodes and any other tumor deposits. People left with no visible cancer, or only deposits smaller than about 1 centimeter, tend to do best. For selected early cancers in someone who wants to be able to become pregnant, removing only the affected ovary and tube may be possible. Chemotherapy is part of treatment for most people. The standard combination is carboplatin, a platinum-based drug, with paclitaxel, given through a vein in cycles over several months. When the cancer is widespread or an operation is too risky at first, chemotherapy may come first to shrink the disease, followed by surgery; in a large trial this order gave similar survival to surgery first. Some people also receive part of their chemotherapy directly into the abdomen through a thin tube. Chemotherapy lowers blood counts, which raises the risk of infection, and paclitaxel can cause numbness or tingling in the hands and feet (neuropathy). After first-line chemotherapy, many people with advanced disease continue with maintenance treatment to delay the cancer's return. PARP inhibitors are daily pills that block a DNA repair system that cancer cells with BRCA changes, or with a related repair defect called homologous recombination deficiency (HRD), rely on to survive. Olaparib (Lynparza) and niraparib (Zejula) are approved for this when the tumor has a BRCA change or tests HRD-positive, which is a main reason tumor and genetic testing matter. In a key trial of people with a BRCA change, olaparib lowered the risk of the cancer worsening or of death by about 70% compared with a placebo. These pills commonly cause tiredness, nausea and anemia and require regular blood count checks. Bevacizumab, an infused drug that blocks the growth of blood vessels tumors need, may be added to chemotherapy and continued afterward, alone or with olaparib. If the cancer returns, options depend largely on timing. Cancer that comes back more than six months after platinum chemotherapy usually responds to platinum again, while cancer that returns sooner is treated with other drugs or in clinical trials. Low-grade serous cancer may be treated with hormone-blocking or targeted drugs, some still under study. Clinical trials are an option at any stage.
First treatment usually stretches over several months: a major abdominal operation and its recovery, a course of chemotherapy, and for many people maintenance treatment that continues afterward. For anyone who has not reached menopause, removing both ovaries brings it on right away, with possible hot flashes, night sweats, trouble sleeping, vaginal dryness and, over time, bone loss. These effects are worth raising early, because several can be eased. Outlook depends most on stage. Across all ovarian cancers in the United States, about 92% of people whose cancer is found while it is still confined to the ovary are alive five years later, compared with about 32% when it has spread to distant parts of the body. Only about one in five cases is found at that early stage. These averages come from people diagnosed several years ago and cannot predict any one person's course. When the cancer was advanced at diagnosis, it often returns after a first remission, sometimes after several years. For many people ovarian cancer then becomes a long-term illness managed with further courses of treatment, separated by periods off treatment. Follow-up visits every few months in the first years include a symptom review, an exam and often CA-125 tests. In a large trial, starting treatment because of a rising CA-125 alone, before any symptoms, did not help people live longer and lowered quality of life, so how closely to track it is a reasonable thing to discuss. Practical help with fatigue, eating and bowel changes, along with counseling and support groups, can make a long course of care more manageable.
See a clinician if bloating, belly or pelvic pain or pressure, feeling full quickly, or a frequent urge to urinate is new and keeps happening or gets worse, particularly after menopause. Ask about genetic counseling if ovarian or breast cancer runs in your family or a relative has a known BRCA or Lynch syndrome gene change. During chemotherapy, call the care team right away for a fever of 100.5 °F (38 °C) or higher, chills or other signs of infection, since infections can become dangerous quickly when blood counts are low. At any point during or after treatment, contact the care team promptly if you keep vomiting, cannot pass stool or gas, or have a swollen, painful belly that does not settle, because the cancer or scar tissue from surgery can block the bowel.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Epithelial Ovarian Cancer is like, what's helped you, or ask the community a question.